141 related articles for article (PubMed ID: 19186672)
1. Orphan disease gains second treatment option.
Morrow T
Manag Care; 2009 Jan; 18(1):47-9. PubMed ID: 19186672
[No Abstract] [Full Text] [Related]
2. Two new drugs for chronic ITP.
Med Lett Drugs Ther; 2009 Feb; 51(1305):10-1. PubMed ID: 19197233
[TBL] [Abstract][Full Text] [Related]
3. [Thrombopoietin-receptor agonists: a revolution in the therapeutic strategies of immune thrombocytopenic purpura?].
Godeau B;
Rev Med Interne; 2009 Mar; 30(3):203-5. PubMed ID: 19019500
[No Abstract] [Full Text] [Related]
4. Glucocorticoids promote response to thrombopoietin-receptor agonists in refractory ITP: a case series.
Poston JN; Gernsheimer TB
Int J Hematol; 2019 Aug; 110(2):255-259. PubMed ID: 30972617
[TBL] [Abstract][Full Text] [Related]
5. New options after first-line therapy for chronic immune thrombocytopenic purpura.
Burzynski J
Am J Health Syst Pharm; 2009 Jan; 66(2 Suppl 2):S11-21. PubMed ID: 19139486
[TBL] [Abstract][Full Text] [Related]
6. Sustaining platelet counts in chronic ITP.
Nurden AT
Lancet; 2011 Jan; 377(9763):358-60. PubMed ID: 20739056
[No Abstract] [Full Text] [Related]
7. [Development of thrombopoietin receptor agonists].
Miyakawa Y
Rinsho Ketsueki; 2009 Oct; 50(10):1434-43. PubMed ID: 19915352
[No Abstract] [Full Text] [Related]
8. Sequential treatment with thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): experience in our center.
González KJ; Zuluaga SO; DaRos CV; Rodríguez PP; Martí AC
Ann Hematol; 2017 Mar; 96(3):507-508. PubMed ID: 27975127
[No Abstract] [Full Text] [Related]
9. New-generation drugs that stimulate platelet production in chronic immune thrombocytopenic purpura.
Nurden AT; Viallard JF; Nurden P
Lancet; 2009 May; 373(9674):1562-9. PubMed ID: 19324405
[TBL] [Abstract][Full Text] [Related]
10. New treatments for idiopathic thrombocytopenic purpura: rethinking old hypotheses.
Arnold DM; Nazi I; Kelton JG
Expert Opin Investig Drugs; 2009 Jun; 18(6):805-19. PubMed ID: 19426124
[TBL] [Abstract][Full Text] [Related]
11. Idiopathic thrombocytopenic purpura resistant to eltrombopag, but cured with romiplostim.
Piccin A; Amaddii G; Natolino F; Billio A; Cortelazzo S
Blood Transfus; 2014 Jan; 12 Suppl 1(Suppl 1):s149-50. PubMed ID: 23736912
[No Abstract] [Full Text] [Related]
12. [New therapeutic possibilities in chronic ITP in adults].
Jönsson S; Olsson B; Wadenvik H
Lakartidningen; 2009 May 20-Jun 2; 106(21-22):1476-9. PubMed ID: 19579436
[No Abstract] [Full Text] [Related]
13. A decision framework for treating chronic immune thrombocytopenia with thrombopoietin receptor agonists.
Dolph M; Roy A; Bhor M; Hearnden J; Kwon CS; Forsythe A; Tremblay G; Briggs A
J Comp Eff Res; 2018 Aug; 7(8):775-784. PubMed ID: 29848048
[No Abstract] [Full Text] [Related]
14. Eltrombopag--an oral thrombopoietin agonist.
Sharma V; Randhawa H; Sharma A; Aggarwal S
Eur Rev Med Pharmacol Sci; 2012 Jun; 16(6):743-6. PubMed ID: 22913204
[TBL] [Abstract][Full Text] [Related]
15. Fibroproliferative activity in patients with immune thrombocytopenia (ITP) treated with thrombopoietic agents.
Ghanima W; Junker P; Hasselbalch HC; Boiocchi L; Geyer JT; Feng X; Gudbrandsdottir S; Orazi A; Bussel JB
Br J Haematol; 2011 Oct; 155(2):248-55. PubMed ID: 21902682
[TBL] [Abstract][Full Text] [Related]
16. New therapy options for chronic immune thrombocytopenic purpura: a breath of fresh air. Introduction.
Francesco R
Eur J Haematol Suppl; 2009 Mar; (71):1-2. PubMed ID: 19200300
[No Abstract] [Full Text] [Related]
17. Reciprocal absence of cross-resistance between eltrombopag and romiplostim in two patients with refractory immune thrombocytopenic purpura.
Scaramucci L; Giovannini M; Niscola P; Tendas A; Perrotti A; De Fabritiis P
Blood Transfus; 2014 Oct; 12(4):605-7. PubMed ID: 25351191
[No Abstract] [Full Text] [Related]
18. Therapy induced iron deficiency in children treated with eltrombopag for immune thrombocytopenia.
Lambert MP; Witmer CM; Kwiatkowski JL
Am J Hematol; 2017 Jun; 92(6):E88-E91. PubMed ID: 28240793
[No Abstract] [Full Text] [Related]
19. Thrombopoietin mimetics for systemic lupus erythematosus with antiphospholipid antibodies should be discussed separately.
Kanda M; Atsumi T
Lupus; 2018 Oct; 27(11):1876-1877. PubMed ID: 29958500
[No Abstract] [Full Text] [Related]
20. [Economic evaluation of Thrombopoietin Receptor Agonists in the treatment of chronic primary immune thrombocytopenia].
Parrondo J; Grande C; Ibáñez J; Palau J; Páramo JA; Villa G
Farm Hosp; 2013; 37(3):182-91. PubMed ID: 23789796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]